ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Deferred Liabilities
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Deferred Liabilities of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2023-03-06
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for the quarter ending 2021-12-31 was $57.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for the quarter ending 2021-09-30 was -$222.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for fiscal 2021 was $396.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in deferred liabilities for fiscal 2020 was -$75.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $57.00K derived: sum of 3 quarters · filed 2023-03-06 | -$165.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $57.00K derived: sum of 2 quarters · filed 2023-03-06 | -$165.00K derived: sum of 3 quarters · filed 2023-03-06 | -$106.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$165.00K derived: sum of 2 quarters · filed 2023-03-06 | -$106.00K derived: sum of 3 quarters · filed 2023-03-06 | $396.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | -$222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$163.00K derived: sum of 2 quarters · filed 2022-11-07 | $339.00K 10-Q · filed 2022-11-07 | $306.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $561.00K 10-Q · filed 2022-08-11 | $528.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $502.00K 10-Q · filed 2022-05-12 | $469.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$75.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$42.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |